Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 5,000 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 5,000 shares of the firm’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $57.03, for a total transaction of $285,150.00. Following the completion of the sale, the vice president now directly owns 33,492 shares of the company’s stock, valued at approximately $1,910,048.76. This represents a 12.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Patrick Lamy also recently made the following trade(s):

• On Monday, December 16th, Patrick Lamy sold 1,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $29.13, for a total transaction of $29,130.00.
• On Tuesday, December 10th, Patrick Lamy sold 925 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.79, for a total value of $28,480.75.

Akero Therapeutics Stock Performance

Shares of AKRO stock opened at $54.00 on Thursday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The company has a market capitalization of $3.77 billion, a price-to-earnings ratio of -14.40 and a beta of -0.19. Akero Therapeutics, Inc. has a one year low of $15.32 and a one year high of $58.40. The company’s 50-day moving average is $29.31 and its 200 day moving average is $28.51.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). Sell-side analysts expect that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Simplify Asset Management Inc. increased its holdings in Akero Therapeutics by 15.6% in the 3rd quarter. Simplify Asset Management Inc. now owns 283,766 shares of the company’s stock worth $8,141,000 after buying an additional 38,279 shares in the last quarter. FMR LLC grew its stake in shares of Akero Therapeutics by 732.1% in the third quarter. FMR LLC now owns 30,337 shares of the company’s stock worth $870,000 after acquiring an additional 26,691 shares during the period. SG Americas Securities LLC raised its holdings in shares of Akero Therapeutics by 4,022.1% during the fourth quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock valued at $16,636,000 after purchasing an additional 583,486 shares during the last quarter. Barclays PLC lifted its position in Akero Therapeutics by 127.9% during the third quarter. Barclays PLC now owns 127,668 shares of the company’s stock valued at $3,662,000 after purchasing an additional 71,652 shares during the period. Finally, Propel Bio Management LLC boosted its holdings in Akero Therapeutics by 4.9% in the third quarter. Propel Bio Management LLC now owns 343,729 shares of the company’s stock worth $9,862,000 after purchasing an additional 15,977 shares during the last quarter.

Analyst Ratings Changes

A number of research firms have recently commented on AKRO. Citigroup raised their target price on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday. Canaccord Genuity Group boosted their target price on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a report on Tuesday. Morgan Stanley increased their price target on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, HC Wainwright lifted their price target on shares of Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a research report on Monday. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.57.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.